"De-extinction" takes center stage as environmentalists express dismay over erosion of the Endangered Species Act ...

A group of experts cautions that the lack of specific rules for genome-edited crops may hurt transparency, while the ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Explore CRISPR Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CRSP. CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be ...

Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. CRISPR Therapeutics (NasdaqGM:CRSP) recently announced its Q1 2025 earnings, reporting a 71% ...

In May of that year, a team at the University of California, Berkeley, filed its first patent application in the U.S. for CRISPR-Cas9. In December, a different team at the Broad Institute of MIT ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

Molecular Biology is the field of biology that studies the composition, structure and interactions of cellular molecules such as nucleic acids and proteins that carry out the biological ...